The Memory Disorders Center and Clinical Research Center at Hawaii Pacific Neuroscience became one of top 30 dementia clinics in the US awarded the ADVANCE (Addressing Dementia Via Agitation-Centered Evaluation) research study.
This is a Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects With Dementia of the Alzheimer’s Type. Study participants will receive the study drug (AXS-05), an active control (bupropion), or a placebo control (inactive substance) orally as a tablet taken twice daily for five consecutive weeks. Study participants will also receive study-related medical exams and laboratory tests at no cost. Compensation for time and travel may also be available.
65-90 years old
Has Alzheimer’s Dementia
Has Agitation due to Alzheimer’s